However, a new drug (DT2216) was synthesized by several modifications of ABT263 and was included in a VHL-recruiting PROTAC that demonstrated their capacity for linking to BCL-xL/2; however, this new drug did not report capacity for linking to the BCL2 isoform, and consequently, this PROTAC was not used in BCL2-dependent T-cell acute lymphoblastic leukemia and T-cell lymphoma. This evidence concerns the gene BCL2 and T-cell non-Hodgkin lymphoma.